See more : MIRAIT ONE Corporation (1417.T) Income Statement Analysis – Financial Results
Complete financial analysis of Nexalin Technology, Inc. (NXL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nexalin Technology, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- BlueBet Holdings Ltd (BBT.AX) Income Statement Analysis – Financial Results
- Prima Marine Public Company Limited (PRM-R.BK) Income Statement Analysis – Financial Results
- Geo Limited (GEO.NZ) Income Statement Analysis – Financial Results
- 3DShopping.com (THDS) Income Statement Analysis – Financial Results
- Mechema Chemicals International Corp. (4721.TWO) Income Statement Analysis – Financial Results
Nexalin Technology, Inc. (NXL)
About Nexalin Technology, Inc.
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 110.75K | 1.32M | 144.07K | 242.91K | 207.38K |
| Cost of Revenue | 25.69K | 363.21K | 21.44K | 29.04K | 218.21K |
| Gross Profit | 85.06K | 958.15K | 122.62K | 213.88K | -10.83K |
| Gross Profit Ratio | 76.80% | 72.51% | 85.12% | 88.05% | -5.22% |
| Research & Development | 1.92M | 511.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 5.78M | 2.79M | 6.14M | 3.47M | 78.13K |
| Selling & Marketing | 0.00 | 886.41K | 35.49K | 10.71K | 1.38M |
| SG&A | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Other Expenses | 0.00 | 171.68K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.78M | 2.79M | 6.14M | 3.47M | 1.46M |
| Cost & Expenses | 5.81M | 3.15M | 6.16M | 3.50M | 1.67M |
| Interest Income | 0.00 | 59.38K | 82.32K | 78.68K | 80.99K |
| Interest Expense | 38.84K | 59.38K | 82.32K | 78.68K | 80.99K |
| Depreciation & Amortization | 4.25K | 5.72K | 537.00 | 429.00 | 535.00 |
| EBITDA | -5.69M | -1.83M | -6.00M | -3.32M | -1.47M |
| EBITDA Ratio | -5,139.63% | -125.69% | -4,177.33% | -1,341.21% | -706.72% |
| Operating Income | -5.70M | -1.83M | -6.02M | -3.26M | -1.47M |
| Operating Income Ratio | -5,143.48% | -138.72% | -4,177.70% | -1,341.38% | -706.98% |
| Total Other Income/Expenses | 1.05M | 135.22K | -59.40K | -145.08K | -3.56M |
| Income Before Tax | -4.65M | -1.70M | -6.08M | -3.40M | -5.02M |
| Income Before Tax Ratio | -4,197.56% | -128.49% | -4,218.93% | -1,401.11% | -2,421.22% |
| Income Tax Expense | 0.00 | 228.00K | 82.32K | 78.68K | 5.00 |
| Net Income | -4.65M | -1.93M | -6.16M | -3.48M | -5.02M |
| Net Income Ratio | -4,197.56% | -145.75% | -4,276.07% | -1,433.50% | -2,421.22% |
| EPS | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| EPS Diluted | -0.63 | -0.26 | -0.85 | -0.48 | -0.69 |
| Weighted Avg Shares Out | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
| Weighted Avg Shares Out (Dil) | 7.36M | 7.29M | 7.28M | 7.28M | 7.28M |
FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
HOUSTON, TX, May 22, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to announce its new division, Nexalin America, has been selected to join the National Traumatic Brain Injury (TBI) Registry Coalition...
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has...
Nexalin Technology CEO Provides Letter to Shareholders
Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes New method of use patent covers key aspects of the technology that enable patients to receive...
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veterans
Nexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury (mTBI). The company said that the study, conducted at the University...
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
Previously served as Acting General Counsel to the Department of Veterans Affairs Previously served as Acting General Counsel to the Department of Veterans Affairs
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology
Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
Event hosted by the U.S. Army Medical Research and Development Command's (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA)
Source: https://incomestatements.info
Category: Stock Reports